Urolithiasis stands as a prevalent ailment within the urinary system, with hyperoxaluria and hypocitraturia being the most frequent manifestations characterized by excessive oxalic acid (OA) and deficient citric acid (CA) levels in urine. Detecting these compounds in urine quantitatively holds paramount importance for early urolithiasis screening. Existing methodologies fall short in achieving simultaneous and on‐site identification of OA and CA, posing challenges for accurate urolithiasis screening. Addressing this concern, the study successfully accomplishes the concurrent identification of OA and CA in urine through a combination of dual‐spectral analysis and biomimetic peroxidase utilization. Bovine serum albumin and dithiothreitol‐modified copper nanoclusters (BSA‐DTT‐CuNCs) are employed as biomimetic peroxidases, effectively mitigating interference and enabling the simultaneous determination of OA and CA. The quantification range spans from 0 to 12 mm for OA and 0.5 to 2.5 mm for CA, with detection limits of 0.18 and 0.11 mm, respectively. To facilitate swift and on‐location urine analysis, a fully automated urine analyzer (FAUA) is introduced that streamlines the process of biomarker pretreatment and identification within urine samples. Validation with real urine samples from urolithiasis patients demonstrates the method's diagnostic precision, highlighting the dual‐spectral technique and analyzer's promising role in urolithiasis screening. A dual‐spectrum detection strategy based on BSA‐DTT‐CuNCs/NADH/phenol‐AAP is innovatively developed, enabling simultaneous detection of citric acid (CA) and oxalic acid (OA) in urine. Coupled with an innovative, fully‐automatic instrument that integrates sample pretreatment and detection, urine samples from patients with kidney stones are accurately identified, underscoring the method's feasibility and practical value.